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Abstract
Background: Cutaneous leishmaniasis (CL) is a disfiguring disease that confronts clinicians with a quandary: leave patients
untreated or engage in a complex or toxic treatment. Topical treatment of CL offers a practical and safe option. Accordingly,
the treatment of CL with WR279,396, a formulation of paromomycin and gentamicin in a hydrophilic base, was investigated
in a phase 2 clinical study in Tunisia and France.
Methods: A phase 2, randomized, double blind, vehicle-controlled study was conducted to assess the safety and efficacy of
topical WR279,396 when applied twice a day for 20 days as treatment for parasitologically confirmed CL. The study protocol
established the primary efficacy end point as complete clinical response (CCR) defined as 50% or greater reduction in the
ulceration size of an index lesion by day 50 (D50) followed by complete re-epithelialization by D100, and no relapse through
D180.
Results: Ninety-two subjects were randomized. Leishmania major was identified in 66 of 68 isolates typed (97%). In the
intent-to-treat population, 47 of 50 WR279,396 treated participants (94%) met the definition of CCR, compared with 30 of 42
vehicle-placebo participants (71%) [p=0.0045]. Erythema occurred in 30% and 24% of participants receiving WR279,396 and
placebo, respectively [p=0.64]. There was no clinical or laboratory evidence of systemic toxicity.
Conclusion: Application of WR279,396 for 20 days was found to be safe and effective in treating L. major CL, and offers great
potential as a new, simple, easily applicable, and inexpensive topical therapy for this neglected disease.
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Introduction
The incidence of cutaneous leishmaniasis (CL) globally is 1.0–
1.5 million cases annually [1]. There are several available
therapeutic options, but none is optimal [2]. In Tunisia, the
standard treatment is with intralesional injections of pentavalent
antimonials [2] the recommended drugs used for the treatment of
both visceral leishmaniasis and cutaneous leishmaniasis, first
introduced 60 years ago.
Intralesional injections are painful, and they are difficult to
administer to children, to patients with multiple lesions, or when
lesions are located on the extremities [3,4]. In such cases systemic
antimony is often administered, despite its cost (US$50–200 per
course), variable efficacy [2,5], and potential or frank toxicity
[2,6].
Topical therapy of CL is an approach that is potentially
efficient, practical and safe [7], yet a product fulfilling all those
www.plosntds.org 1 May 2009 | Volume 3 | Issue 5 | e432requirements has not yet been identified [8]. The aminoglycoside
paromomycin is the most studied compound as a potential topical
treatment for CL [9], and parenterally it is being aggressively
pursued as a highly effective treatment for human visceral
leishmaniasis [10]. As a class, aminoglycosides accumulate in
lysosomes [11] where Leishmania multiply, and offer the potential to
be highly effective therapeutics.
In topical preparations, paromomycin is a component of two
antileishmanial products currently available outside the Interna-
tional Conference of Harmonization zone (ICH for USA, EC, and
Japan). The first, developed by El-On [12] and marketed in Israel
as Leshcutan, contains 15% paromomycin and 12% methyl-
benzenthonium chloride (MBCL) in white soft paraffin. It has
demonstrated good efficacy in treating CL [13,14] but its
usefulness is hampered by increased incidence of dermatologic
irritation attributable to the MBCL [13,14,15,16,17]. The second
formulation combines paromomycin (no MBCL) with urea and
while non-irritating its efficacy remains largely undistinguished,
with reported cure rates little better than placebo in Iran (47% v.
44%) and Tunisia (27% v. 18%) [18,19,20].
WR279,396 is a hydrophilic formulation of paromomycin 15%
plus a second aminoglycoside (gentamicin 0.5%), that was
developed in order to exploit the antileishmanial efficacy of the
aminoglycosides while eliminating the potential for the skin
irritation caused by MBCL. In this preparation, the addition of
gentamicin has been shown to increase the antileishmanial efficacy
of paromomycin in rodents [21]. In a Balb/c mouse model of CL,
WR279,396 cured lesions caused by L. major (MON-4), L.
amazonensis, L. mexicana, and L. panamensis strains in 100% of the
mice without subsequent relapse [21]. These results were recently
confirmed in a C57Bl/6 L. major MON-26 model [22]. In a pilot
study in humans in the New World (L. panamensis), WR279,396
was well tolerated and shortened cure time, but had no effect on
the overall cure rate at six months [23].
Herein, we report the results of a recently completed phase 2,
randomized, double blind, vehicle-controlled trial in Tunisia and
France to assess the efficacy and safety of topical WR279,396
administered twice a day for 20 days for the treatment of patients
with CL caused by L. major.
Methods
Study Participants
Eligible participants were from the Sidi Bouzid governorate
(Central Tunisia), where L. major MON-25 is endemic, and
travelers returning to Paris from L. major-endemic areas in North
and Sahelian Africa, who had skin lesions that were suspected to
be CL. Criteria for inclusion were age between 5 and 75 years, the
presence of parasitologically confirmed CL, lesions that were
primarily ulcerative (i.e., not purely verrucous or nodular) and
measured $1c m
2 and #5c m
2. Criteria for exclusion were
history of known or suspected hypersensitivity or idiosyncratic
reactions to aminoglycosides; previous use of antileishmanial drugs
(within 3 months) or nephrotoxic or ototoxic drugs; prior diagnosis
of leishmaniasis; more than 5 lesions, or a lesion in the face that in
the opinion of the attending dermatologist could potentially cause
significant disfigurement; significant medical problems as deter-
mined by history or laboratory studies; breast feeding and
pregnancy. Participants also had to have normal Romberg tests
and no relevant findings on baseline audiometry. In cases where
the participant presented more than one lesion, investigators
treated all lesions as per protocol with the same blinded study
treatment as the index lesion.
Study Design
The study was a phase 2, randomized, double blind, vehicle-
controlled, multi-center trial. Participants were randomized in a
1:1 allocation ratio to receive either WR279,396 or placebo-
vehicle, each of which was applied twice daily for 20 days and
covered with an occlusive dressing (Tegaderm, 3M Laboratory,
Saint Paul, MN). Investigators, who were blinded to whether
participants received WR279,396 or placebo-vehicle, evaluated
lesions for clinical response on D20 (i.e., the end of the treatment
period), D50 (i.e., 30 days after the conclusion of treatment),
D100, and D180.
A sequence of genuine random numbers for the randomization
procedure was obtained from the ‘‘fourmilab.ch/hotbits’’ website
by a member of the Department of Chemical Information, Walter
Reed Army Institute of Research, Silver Spring, Maryland and
purged of duplicates. The random numbers are generated by a
process which takes advantage of the inherent uncertainty in the
quantum mechanical laws of nature. Specifically, they are
generated by timing successive pairs of radioactive decays detected
by a Geiger-Mu ¨ller tube interfaced to a computer. This process is
better than the pseudo-random number algorithms typically used
in computer programs. The randomization of the study drugs was
done by an independent group, Fischer BioServices, Rockville,
Maryland a contractor to The U.S. Army Medical Research
Acquisition Activity (USAMRAA), Ft. Detrick, Maryland.
Endpoints
The study protocol established the primary efficacy end point as
complete clinical response (CCR), defined as complete reepithe-
lialization (i.e., length6width of ulceration=060) of the index
lesion by D50 or a .50% reepithelialization by D50 followed by
complete reepithelialization on or before D100 with no relapse
ever having occurred from D50 through D180. Relapse was
defined as an increase in the area of ulceration relative to the
previous measurement. Participants who did not complete the
180-day period of observation were considered to have failed to
achieve CCR because relapse could not be fully assessed. The
Author Summary
Cutaneous leishmaniasis is due to a small parasite
(Leishmania) that creates disfiguring sores, and affects
more than one million persons (mainly children) each year.
Treating lesions with a cream—instead of with injections
as currently done—would greatly improve the well-being
of affected patients. No cream formulation that would be
efficient and would not create important skin irritation has
been identified yet. Here, we tested a new cream
formulation (WR279,396) containing paromomycin and
gentamicin, two members of a well-known family of
antibacterial antibiotics (aminoglycosides). Injectable par-
omomycin is efficient in other forms of the disease (visceral
leishmaniasis). This was a carefully monitored study (phase
2) involving mainly children in Tunisia and France. The
cream was applied twice a day for 20 days. The proportion
of patients treated with the paromomycin-containing
cream (active formulation) that cured (94%) was higher
than that observed (71%) in patients treated with a cream
that did not contain the active product (placebo formu-
lation). Local irritation affected less than one-third of the
patients and was usually mild. This new cream formulation
was safe and effective in treating cutaneous leishmaniasis,
thereby providing a new, simple, easily applicable, and
inexpensive treatment for this neglected disease.
Topical Treatment of Cutaneous Leishmaniasis
www.plosntds.org 2 May 2009 | Volume 3 | Issue 5 | e432index lesion was defined as the uppermost, primarily ulcerative,
parasitologically positive lesion on the body (excluding the ears) or,
if two lesions were equally uppermost, the left uppermost primary
ulcerative lesion. The secondary endpoint was the safety and
tolerance of WR279,396.
Procedures
The primary performing Institutions were the Institut Pasteur in
Tunis, Tunisia, and the Medical Center Institut Pasteur, in Paris,
France. Investigators measured all lesions in two perpendicular
directions and took photographs at the following time points: prior
to therapy, at the end of therapy (D20), and at 30 days (D50), 80
days (D100), and 6 months (D180) after the end of therapy.
Medical personnel applied study drug (i.e., placebo-vehicle or
WR279,396) twice daily for 20 days to all CL lesions present at
baseline at a dose of 0.05 ml per 1 cm
2 of CL lesion at a primary
health facility in Tunisia and at the Medical Center of the Institut
Pasteur in Paris. Each CL lesion was cleaned with soap and water
and sterile 0.9% saline, and then dried using sterile USP Type VII
Gauze sponges before application of study drug. Next, medical
personnel dispensed study drug directly onto the ulcer from a pre-
loaded 1 ml syringe without a needle, and spread drug over the
ulcer using the finger of a disposable glove so as to penetrate even
under the ulcer’s borders. Study drug was to remain undisturbed
(i.e., not wiped off and not wetted) for 4 hours after each
application, so the adhesive polyurethane film dressing, Tega-
derm, was applied over the top of the lesion following drug
application. Investigators observed each participant for 30 minutes
after application of study drug. Lesions and surrounding skin were
evaluated for pain, erythema, and edema each day that the topical
creams were administered and at follow-up study visits. The
participants were also observed and questioned daily for the
occurrence of systemic side effects (e.g., vertigo, tinnitus) using a
standardized questionnaire. Diminished hearing was verified with
the Danplex S42 audiometer (GN Otometrics, Maarkaervej 2A,
DK-2630, Taastrup, Denmark). Clinical and laboratory evidence
of side effects was determined on D10 and D20 by changes from
baseline in serum creatinine, hearing, and Romberg tests. A
Digmatic Caliper, Mitutoyo Corporation, model No. CD-6CS
with a resolution of 0.01 mm and an accuracy of 60.002 mm was
used to measured lesions size. Lesions were measured by a trained
investigator that followed a Study Specific Procedure (SSP-
279396-01-003) in two perpendicular directions; in its greatest
dimension, and at 90 degrees to the first measurement. Patients
were not given incentives to come back for follow-up visits;
patients were actively followed-up.
Ethical and Regulatory Issues
Before entry into the study, investigators obtained written
informed consent from all participants or, for pediatric partici-
pants, from parents/guardians. Comparison of WR279,396 to
placebo-vehicle was justified for several reasons: CL caused by L.
major is self-limiting and heals without treatment after several
months. Furthermore, the trial allowed participants whose
condition worsened to withdraw from the study and receive
standard therapy. In addition vehicle application provided the
following advantages: (i) protection against bacterial infection by
keeping the lesion(s) clean and occluded; (ii) direct access to the
medical team that performed the medical history, physical exam,
dermatology exam, and laboratory test ; and (iii) complete
parasitological diagnosis.
The study protocol (Principal Investigator Dr. Max Gro ¨gl), case
report form, and SOPs were approved in the United States by the
Walter Reed Army Institute of Research, Scientific Research
Committee. A second level review of the protocol, consent form
and all amendments was conducted by the Human Subjects
Research Review Board (HSRRB), Commanding General, U.S.
Army Medical Research and Materiel Command (USAMRMC),
the Medical Ethical Committee of the Institut Pasteur de Tunis,
Tunisia, and the Consultation Committee for the Protection of
Individuals in Biomedical Research at Hospital Tarnier-Cochin,
Paris, France. The study was conducted in accordance with Good
Clinical Practice (GCP) under an Investigational New Drug (IND)
application submitted to FDA. The Direction de la Pharmacie et
des Me ´dicaments, Ministe `re de la Sante ´ Publique, Tunisia, and
the Agence Franc ¸aise de Se ´curite ´ Sanitaire des Produits de Sante ´
were informed of the trial. This study was conducted in
accordance with ethical principles that have their origins in the
Declaration of Helsinki and the Belmont Report. The Quality
Assurance Office of the U.S. Army Medical Materiel Develop-
ment Activity monitored the study.
Drugs
WR279,396 is an off-white to yellowish, thick cream containing
15% (w/w) paromomycin-sulfate (Farmitalia) and 0.5% (w/w)
gentamicin-sulfate (Schering) as active components. Study drugs
were manufactured by the University of Iowa, College of
Pharmacy under Good Manufacturing Practice (GMPs). The
placebo consisted of the vehicle without the active components
and trace amounts of coloring agents to match the appearance and
maintain the blind.
Parasitologic Studies
Each lesion to be evaluated for efficacy was aspirated and/or
scraped and/or biopsied. Proof of infection was documented
through either the demonstration of motile promastigotes in
aspirate cultures or the microscopic identification of Leishmania
amastigotes in material obtained from CL lesions. Iso-enzyme [24]
and/or PCR [25] analysis of the parasites isolated from the CL
lesions was completed after study treatment had been started. Iso-
enzyme and PCR analyses were carried out according to
published protocols [24,25].
Statistical Analysis
The protocol calculated a sample size of 50 participants per
group with 80 percent power and a Type I error rate of 5 percent
to detect a 30 percent difference in the proportion of participants
achieving CCR, assuming a CCR proportion of 35 percent in the
placebo-vehicle group and 65 percent in WR279,396 participants,
with a 5% expected rate of loss to follow-up.
Analyses included all randomized participants under the
intention-to-treat principle and the randomization was coordinat-
ed between the two clinical sites. Continuous data were compared
using the Wilcoxon rank-sum test and categorical data were
compared using the Fisher’s exact test. StatXact version 7 (Cytel
Software Corporation, Cambridge, MA) was used to calculate
95% exact confidence intervals (CIs) of the difference in the
proportion achieving CCR with the option to compute a CI on the
difference of two binomial proportions based on the standardized
statistic and inverting two one-sided tests. A log-rank test was used
to compare time to reepithelialization without relapse. Because the
trial collected data on clinical response only at discrete time-points,
namely the D20, D50, D100, and D180 visits, the time-to-event
analysis grouped reepithelialization times according to the visit at
which investigators observed the event. To adjust for baseline
differences, a linear model for the proportion of participants
achieving CCR was fit for each baseline variable of interest with
covariates for treatment group and the baseline variable. To
Topical Treatment of Cutaneous Leishmaniasis
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subgroups, we calculated the Breslow-Day test for homogeneity
of the odds ratio
Results
Between March 2003 and January 2005, 142 participants (27 in
Paris and 115 in Sidi Bouzid, Tunisia) were screened, of whom 92
(10 in Paris and 82 in Sidi Bouzid, Tunisia) underwent
randomization; 50 were assigned to the WR279,396 group and
42 to the placebo-vehicle control group (Figure 1). The study was
conducted over at least one entire leishmaniasis season. Figure 1
presents the distribution of participants from screening until study
completion in the two treatment groups for both sites. Forty-nine
of 50 participants randomized to WR279,396 and 41 of 42
participants randomized to placebo-vehicle completed the study.
All participants had lesions that were parasitologically confirmed
by smear, culture or both. Iso-enzyme testing of 18 isolates (8
isolates from the Paris site and 10 from Tunisia) identified L. major
in 17 participants and L. infantum in one participant, who was from
the French site. L. major isolates from the Paris site were MON-
74, MON-26, MON-25, -, and all L. major isolates from Tunisia
were MON-25. Fifty isolates from Tunisia were tested using PCR,
which identified L. major in 49 participants and L. tropica in one
participant. In total, L. major was identified in 66 of 68 isolates
typed (97%). With one exception, applications of study drugs were
conducted according to the protocol. In this one case, treatment
was stopped after only 12 applications (6 days) due to skin
irritation and conjunctivitis that resulted from inadvertent contact
of study drug to the eye while sleeping. However, this participant’s
lesion rapidly improved without any subsequent therapy allowing
follow-up evaluations to be conducted as per protocol. All 92
participants received study drug (either placebo-vehicle or
WR279,396). Except for 2 participants, who withdrew voluntarily
from the study during or following the 20-day treatment period to
receive alternative therapy (Figure 1), no participant was lost to
follow-up, and all major end-points were accessible for all.
Overall, the two treatment groups were similar in baseline
demographics and disease characteristics (Table 1). A greater
proportion of placebo-vehicle participants were 18 or older
compared to WR279,396 participants. Because participants at the
Medical Center Institut Pasteur in Paris contracted CL while
traveling, a greater proportion of participants were 18 years or older
compared to Tunisian participants. Fifty-four participants had a
single lesion at baseline. The distributions of lesion area, both of the
index lesion and of all baseline lesions, were roughly equivalent
between the groups. Forty percent of participants in each treatment
group had the index lesion above the belt, and all but two
WR279,396 participants had the index lesion on the limbs. The
median number of days before treatment since participants first
noticed a baseline CL lesion/papule was 62 in both groups.
Efficacy Analysis
Primary analysis, complete clinical response (CCR) -
index lesion. Among the 50 WR279,396-treated participants,
47 (94%) met the definition of CCR, compared with 30 of the 42
placebo-vehicle participants (71%) (p=0.0045), resulting in an
estimated difference of 23% in favor of WR279,396 participants
(95% exact CI: 6, 39). The reasons for failure in the 3 participants
treated with WR279,396 were: (i) two participants had less than
50% reepithelialization at D50 (although one participant
completely healed 1 week later without further therapy), (ii) one
participant was considered a treatment failure in the intent-to-treat
analysis because he requested to be withdrawn and switched to
intralesional antimony. The single WR279,396-treated participant
who completed only 6 days of treatment cured despite such a short
course. Among the 12 placebo-vehicle participants who failed, in 8
participants the ulcer either increased in size or decreased by less
than 50% by D50, 3 participants relapsed, and 1 who withdrew
voluntarily from the study was lost to follow-up and considered a
failure in the intent-to-treat analysis.
Complete reepithelialization of index lesion without
relapse. Figure 2 shows the time course of complete
reepithelialization (i.e, 060 ulceration) without relapse of the index
Figure 1. Flowchart summarizing the enrolment, randomization and follow-up of patients. Values are numbers of patients as follows:
Total number of patients (Number at Tunisian site/number at French site).
doi:10.1371/journal.pntd.0000432.g001
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day of topical application), the proportion of placebo-vehicle
participants achieving complete reepithelialization without
subsequent relapse was initially higher than for WR279,396
participants (43 versus 20 percent). By D50, however, 86 percent of
WR279,396-treatedand64percentofplacebo-vehicleparticipantshad
complete reepithelialization of the index lesion without subsequent
relapse.Thecrossingofthetime-to-eventcurvesbetweenD20andD50
is reflected in the log-rank test, which failed to detect a difference in the
distribution of time to reepithelialization (p=0.33).
Relapses. Clinical relapse of the index lesion following
completion of the 20-day course of treatment was observed in 3
participants, all from the placebo-vehicle group. No clinical
relapse of the index lesion or non-index lesion occurred in the
WR279,396 group.
Analysis by participant incorporating all treated
lesions. Rather than restrict the analysis to the index lesion,
we compared CCR by treatment group for all treated lesions, i.e.,
patient cure. Response status for the 28 (56%) WR279,396
participants and 26 (62%) placebo-vehicle participants whose
index lesion was the only treated lesion are identical to that of the
primary analysis. For the 38 participants who investigators treated
at multiple lesions, participants are classified as having CCR only
if all lesions met the definition of CCR. When considering all
treated lesions, results were similar to the categorization for index
lesions (Table 2).
In summary, regardless of the criterion used to analyze the data,
the proportion of lesions and participants with a positive outcome
by D50 was significantly greater in the WR279,396-treated group
than in the placebo-vehicle group.
Evolution in non L. major Cases
Two participants were confirmed to be infected with a non-L.
major species. One was infected with L. infantum and the other with
L. tropica. Self-healing occurs less frequently with both species than
Table 1. Baseline Characteristics of the Participants.
WR279,396 (N=50) Placebo-Vehicle (N=42) P Value
Center – no. (%)
Paris, France 5 (10) 5 (12) 1.0
Sidi Bouzid, Tunisia 45 (90) 37 (88)
Male sex – no. (%) 27 (54) 27 (64) 0.40
Age ,18 years – no. (%)
Overall 47 (94) 33 (79) 0.034
Paris, France (N=10) 2 (40) 0 (0)
Sidi Bouzid, Tunisia (N=82) 45 (100) 33 (89)
Lesions – no. (%)
1 28 (56) 26 (62) 0.67{
2 9 (18) 7 (17)
3 9 (18) 4 (10)
4 or 5 4 (8) 5 (12)
Total lesion area – mm
2
Median 128 154 0.52
Interquartile range 85 to 223 70 to 264
Index lesion area – mm
2
Median 92 115 0.34
Interquartile range 55 to 141 50 to 172
Index lesion on upper body – no. (%) 20 (40) 17 (40) 1.0
Index lesion on extremity – no. (%) 48 (96) 42 (100) 0.50
Days before treatment since lesion first noticed
Median 62 62 0.96
Interquartile range 38 to 79 39 to 79
Leishmania species – no. (%)
L. major 32* (64) 24* (57) 0.53{
L. infantum 1 (2) 0 (0)
L. tropica 1 (2) 0 (0)
Unidentified 16 (32) 18 (43)
Comparisons of categorical variables use the Fisher’s exact test for the entire study cohort, while comparisons of continuous variables use the Wilcoxon rank-sum test.
{Compares the proportion of participants in each group with a sole lesion at baseline.
*Species identification was by isoenzyme electrophoresis (18 isolates), PCR (50 isolates) or both techniques (8 isolates). All isolates identified by both techniques were
from Tunisia and all belonged to the L. major MON-25 zymodem (the only L. major zymodem reported from the Maghreb). In France, identification was by isoenzyme
electrophoresis in 8 cases as follows: L. major MON-25 (5 isolates), L. infantum MON-24, L. major MON-26, L. major MON-74 (1 isolate each).
{Compares the proportion of participants in each group with L. major identified.
doi:10.1371/journal.pntd.0000432.t001
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achieved CCR, although the participant infected with L. infantum
received only 6 days of treatment.
Influence of Baseline Factors on Effect of Treatment
We explored CCR in subgroups defined by baseline character-
istics including number (1 and .1), index lesion area (,100 and
$100 mm
2), location (upper and lower body), and age (,60 and
$60 days) of lesions. After adjustment singly for each baseline factor,
the statistical benefit of WR279,396 over placebo-vehicle remained
(Table 3). Adjustment for age less than 18 years, however, noticeably
lessened the estimate of the treatment effect, with an adjusted
difference in the proportion of CCR of 16 percent (95% CI: 1, 30).
The higher proportion of participants under 18 years achieving
CCR combined with the greater proportion of WR279,396
participants less than 18 was responsible for this. When modeling
lesion number, index lesion area, and lesion age continuously, only
adjustment for index lesion area differed appreciably from the model
where area was modeled categorically. Adjusting for index lesion
area as a continuous covariate resulted in an estimated difference in
the proportion of CCR of 19 percent (95% CI: 4, 34).
No baseline factor appeared to modify the effect of WR279,396,
as indicated by Breslow-Day homogeneity tests, all of which were
above 0.20.
Safety
Topical administration of WR279,396 was generally safe and
well tolerated (Table 4). No death occurred during this clinical
trial, and the only serious adverse event was an arm fracture
unrelated to study medication. Overall, the number of participants
experiencing adverse events was comparable, with roughly a
quarter of participants in each group experiencing an adverse
event. The most commonly reported event was erythema at the
site of application, which occurred in 30 percent of participants
who received WR279,396 and 24 percent of participants who
received placebo-vehicle with onset within 30 minutes of applica-
tion (p=0.64). Mild pain within 30 minutes of application was
reported in roughly 14 percent of participants in each group. No
participant had an increase from baseline serum creatinine
following administration of study drug (D10 and D20). Only mild
increases and decreases in hearing acuity from baseline were
detected on audiometry, occurring with similar frequency in both
groups (28% and 21% in WR279,396 and placebo-vehicle,
respectively; p=0.63). There was no report of vertigo and no
abnormal Romberg test result in participants who received
WR279,396.
Discussion
For a neglected disease like leishmaniasis, the development of a
GMP formulation that is safe and efficacious is a step in the right
direction. There is a general lack of safe, effective, and affordable
pharmaceuticals worldwide to treat or prevent neglected diseases
that disproportionately cause high mortality and morbidity among
the world’s poor in the developing world [26]. Of the many
examples of neglected diseases, L. major CL is perhaps one disease
that should have numerous good solutions by now, yet the
internationally accepted standard treatment remains largely tied to
antimony, even for all the problems associated with its use.
For decades, clinicians caring for patients with CL have been
confronted with a difficult choice: either leave patients untreated (a
common proposal for patients with five or fewer uncomplicated
lesions due to L. major), or engage in a complex or toxic treatment
for this disfiguring, but non life-threatening disease. In this study,
we found that WR279,396 was well-tolerated and induced
complete clinical response (CCR) in a significantly greater
percentage of participants compared to placebo-vehicle in
participants with CL due to L. major. These results raise a strong
possibility that we may exit from this old quandary of how best to
manage patients with L. major CL. Of the 49 participants treated in
the WR279,396 arm, only 1 (2%) failed to achieve complete
reepithelialization of his lesion in less than 2 months. If the efficacy
of WR279,396 can be reproduced in subsequent phase 3 clinical
studies, complex therapeutic decisions in L. major CL may become
the exception rather than the rule.
The time-to-event analysis raised two interesting observations:
First, the response seen with placebo-vehicle was markedly higher
than the response reported in placebo-treated participants in a
Figure 2. Reepithelialization of index lesion without relapse.
doi:10.1371/journal.pntd.0000432.g002
Table 2. CCR at the index lesion and all lesions.
WR279,396 (N=50) Placebo (N=42) Total (N=92) Fisher’s exact p Difference in % (95% CI)
Index lesion
CCR 47 (94%) 30 (71%) 77 (84%) 0.0045 23% (6%, 39%)
No CCR 3 (6%) 12 ( 29%) 15 (16%)
All lesions
CCR 46 (92%) 29 (69%) 75 (82%) 0.0065 23% (6%, 40%)
No CCR 4 (8%) 13 (31%) 17 (18%)
doi:10.1371/journal.pntd.0000432.t002
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1995 (71% versus 32%) [19]. Thus, an intrinsic efficacy of the
vehicle of WR279,396 on CL ulcerations may account for part of
this difference, and for the unexpectedly high placebo cure rate
in the trial reported here. Second, and consistent with our earlier
studies evaluating WR279,396, during the 20-day drug applica-
tion period (between D1 and D20), the mean ulceration area for
WR279,396-treated participants decreased at a slower rate than
in placebo-vehicle treated participants (Figure 2). This initial
transient slowing in ulceration closure was not totally unexpect-
ed. The natural progression of the healing process in CL entails a
decrease in the depth of the ulceration as the parasite load
decreases followed by a reduction in the ulceration width as
re-epithelialization progresses. Thus, in treated participants, the
non-improvement at day 20 of the mean ulceration area may be
linked to the inflammatory response as parasites are killed by
WR279,396. This slower decrease of ulceration area, limited
to the 20-day drug application phase followed by a significant
acceleration in healing after D20, bore no negative clinical
impact. Indeed, only 1 participant in each group requested to
be withdrawn before the major end-point evaluation at
D50. Finally, and perhaps paradoxically, in most patients,
the fact that reepithelialization started after the end of the
20-day application period may actually favor compliance
with this treatment schedule should the drug become widely
available.
WR279,396 continued to demonstrate an excellent safety
profile with very few local and no systemic adverse events
observed. This trend was similar to our previous experience with
this product compiled from pre-clinical, Phase 1, and two earlier
phase 2 studies in the New World [23]. Importantly, this topical
preparation containing two aminoglycosides displayed no
detectable renal or VIIIth cranial nerve toxicity. These safety
observations are in accord with the findings from a recent
study of intramuscular (IM) paromomycin for visceral leishman-
iasis in India, which also showed no clinically significant kidney
or VIIIth nerve toxicity yet the systemic exposure in that IM
study was much greater than from WR279,396 applied topically
[27].
In addition to the promising efficacy observed in this study
against L. major MON-25, data collected thus far indicate that
WR279,396 will likely be broadly effective against a wider variety
of leishmania species. Several key observations support such
optimism. First WR279,396 was efficient not only in L. major
MON-26 [22] , and in L. major MON-4, but also in L. amazonensis,
L. mexicana, and L. panamensis in infected mice [21]. Second
WR279,396 was active in L. panamensis in humans in Colombia
[23]. Third, L. tropica is very sensitive to paromomycin in vitro
[28]. And fourth, but not least, in an L. tropica focus of Turkey, the
paromomycin+MBCL formulation induced a 37.5% cure rate at 4
weeks, suboptimal, but significantly higher than the 0% cure rate
in oral ketoconazole-treated patients [29,30].
Conclusion
The application of WR279,396 for 20 days was found to be safe
and effective (94% cure rate) in treating L. major CL, and offers
great potential as a new, simple, easily applicable, and inexpensive
topical therapy for this neglected disease [31]. L. major CL in North
Africa, Sahelian Africa, and the Middle East, involves tens to
Table 3. Complete Clinical Response (CCR) at the Index Lesion According to Baseline Characteristics.
Subgroup No. of Participants % CCR Difference in %
WR279,396 Placebo Observed (95% CI) Adjusted (95% CI)
Center 22 (7, 37)
Paris, France 10 80 40 40 (215, 95)
Sidi Bouzid, Tunisia 82 96 76 20 (5, 35)
Male sex 22 (7, 37)
Yes 54 93 67 26 (6, 46)
No 38 96 80 16 (26, 38)
Age ,18 years 16 (1, 30)
Yes 80 96 82 14 (0, 28)
No 12 67 33 33 (228, 95)
Single baseline lesion 24 (10, 38)
Yes 54 96 88 8 (26, 22)
No 38 91 44 47 (20, 74)
Index lesion ,100 mm
2 22 (6, 37)
Yes 46 96 78 19 (22, 39)
No 46 91 67 24 (2, 47)
Index lesion on upper body 23 (7, 38)
Yes 37 100 71 29 (8, 51)
No 55 90 72 18 (23, 39)
Lesion noticed ,60 days before treatment 23 (7, 38)
Yes 43 96 70 26 (4, 47)
No 49 93 73 20 (21, 41)
doi:10.1371/journal.pntd.0000432.t003
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children [32]. Health systems are often unable to cope with these
epidemics. In this context, a simple, straightforward treatment is
crucial.
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Table 4. Immediate & Delayed Local & Systemic Toxicity.
REACTION WR279,396 Group (N=50) Placebo-Vehicle Group (N=42)
Participant with










1 7 (14.0) 3.1 6 (14.2) 3.3
Mild 7 (14.0) 3.1 6 (14.2) 3.3
Moderate 0 (0.0) 0 0 (0.0) 0
Severe 0 (0.0) 0 0 (0.0) 0
LOCAL ERYTHEMA
2 15 (30.0) 7.7 10 (23.8) 8.8
Mild 15 (30.0) 6.4 10 (23.8) 7.7
Moderate 5 (10.0) 3.4 2 (4.8) 4.5
Severe 1 (2.0) 2.0 0 (0.0) 0
LOCAL EDEMA
2 1 (2.0) 10.0 2 (4.8) 5.0
Mild 1 (2.0) 6.0 2 (4.8) 5.0
Moderate 1 (2.0) 2.0 0 (0.0) 0
Severe 1 (2.0) 2.0 0 (0.0) 0
SYSTEMIC REACTION 1 (2.0) 1.0 1 (2.4) 2.0
Vertigo 0 (0.0) 0 1 (2.4) 2.0
Tinnitus 1 (2.0) 1.0 0 (0.0) 0
Hearing 0 (0.0) 0 0 (0.0) 0
DELAYED
0
LOCAL PAIN 9 (18.0) 1.6 5 (11.9) 3.2
Mild 9 (18.0) 1.6 5 (11.9) 3.2
Moderate 0 (0.0) 0 0 (0.0) 0
Severe 0 (0.0) 0 0 (0.0) 0
LOCAL ERYTHEMA 15 (30.0) 7.8 11 (26.2) 8.0
Mild 15 (30.0) 6.5 10 (23.8) 7.8
Moderate 4 (8.0) 4.3 3 (7.1) 3.3
Severe 1 (2.0) 2.0 0 (0.0) 0
LOCAL EDEMA 1 (2.0) 11.0 3 (7.1) 3.7
Mild 1 (2.0) 7.0 3 (7.1) 3.7
Moderate 1 (2.0) 2.0 0 (0.0) 0
Severe 1 (2.0) 2.0 0 (0.0) 0
SYSTEMIC REACTION 0 (0.0) 0 2 (4.8) 1.5
Vertigo 0 (0.0) 0 2 (4.8) 1.5
Tinnitus 0 (0.0) 0 0 (0.0) 0
Hearing 0 (0.0) 0 0 (0.0) 0
0Immediate: observed within 30 minutes of application Delayed : Observed just prior to next application.
1Mild pain: does not interfere with daily activity, Moderate pain: interferes with daily activity, Severe pain: daily activities are interrupted.
2Mild: barely perceptible erythema or edema, Moderate: well defined erythema or edema, Severe: very red erythema with raised .2 mm edema.
doi:10.1371/journal.pntd.0000432.t004
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